AG百家乐大转轮-AG百家乐导航_怎么看百家乐走势_全讯网官网 (中国)·官方网站

Research News

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
澳门百家乐官网赢钱秘| 赌百家乐怎样能赢| 百家乐陷阱| 南京百家乐的玩法技巧和规则| 大发888游戏平台hgx2dafa888gw| 北票市| 24山方向上| 大发888信誉| 澳门百家乐官网免费开户| 姚记百家乐官网的玩法技巧和规则| 百家乐跟路技巧| 香港六合彩网址| 现金百家乐下载| 开平市| 百家乐网址是多少| 大发888游戏登陆| 尊龙网站| 战神百家乐娱乐| 拉斯维加斯国际娱乐| 百家乐官网博彩的玩法技巧和规则| 百家乐赢钱公式1| 百家乐官网有哪些注| 百家乐现金游戏注册送彩金| 网上娱乐城| 试玩百家乐官网帐| 德州扑克 梭哈| 百家乐官网5式直缆打法| 瑞鑫棋牌下载| 芝加哥百家乐官网的玩法技巧和规则| 大发888娱乐场电话| 百家乐官网号技巧| 太阳城的故事| 回力百家乐官网的玩法技巧和规则| 大发888官方 3000| 新濠峰百家乐官网的玩法技巧和规则| 威尼斯人娱乐网可信吗| 百家乐官网技巧论坛| 金赞百家乐的玩法技巧和规则| 澳门百家乐官网会出老千吗| 百家乐代理在线游戏可信吗网上哪家平台信誉好安全 | 最好的棋牌游戏|